涩里番
The D2R International Partnerships Program (IPP) supports strategic international collaborations aligned with D2R鈥檚 mission. It fosters formal, institutional partnerships between 涩里番/D2R and leading global organizations to advance joint research.
Partnerships must demonstrate clear added value (e.g., complementarity, synergy, or contextual advantage), support multidisciplinary training, and show strong institutional commitment.
The program prioritizes large-scale initiatives aligned with D2R鈥檚 foundational axes and priority disease areas. D2R will support three to four projects, with up to $600,000 over three years per project, matched primarily by cash contributions from partners.
The application process includes two stages:
- LOI review:听Screens for alignment with D2R priorities; selected applicants proceed.
- Full application review:听Evaluates scientific merit, partnership strength, and strategic fit to inform funding decisions.
International Partnerships Program Awards
| Principal Investigator | Title | Partner(s) |
|---|---|---|
| Guillaume Bourque | Machine learning models for the design of RNA therapeutics: Development of experimental data | Center for iPS Cell Research and Application (CiRA), Kyoto University (Japan), Imec (Belgium), A*STAR (Singapore), and University of Zurich (Switzerland) |
| Mark Lathrop and Yasser Riazalhosseini | A Canada-Germany Partnership for tackling Immune Mediated Disorders (CAGE4IMDs) | Cluster of Excellence ImmunoPreCept, coordinated by Charit茅鈥揢niversit盲tsmedizin (Germany) & Max Delbr眉ck Center (MDC) (Germany), and German Cancer Research Center (DKFZ) (Germany) |
An international research network led by 涩里番 and Kyoto to advance personalized genomic medicine
The network鈥檚 broad research objective is to generate advanced therapeutic models using disease-relevant genomic datasets and iPSC-derived tissues, facilitating biomarker identification and RNA-based therapeutic testing. These platforms will be used to investigate rare, cancerous, cardiovascular, and infectious diseases. Priority will be placed on simplifying manufacturing and screening workflows for gene and cell therapies. Through the sharing of protocols, datasets, and IP agreements, the partnership will promote translational outcomes. With strong EDI components, the initiative will also evaluate ethical, legal, and social considerations across global contexts, aiming to foster regulatory convergence and inclusive innovation.
Principal Investigator: Guillaume Bourque (涩里番)
颁辞-滨苍惫别蝉迟颈驳补迟辞谤:听Raquel Cuella Martin,听Hamed Najafabadi, Carl Ernst, Yann Joly, Nada Jabado, Ioannis Ragoussis, Mark Lathrop, Thomas Duchaine, Ciriaco Piccirillo, Satoshi Yoshiji, Ian Watson, Jacek MajewskI, Sirui Zhou, Simon Gravel, Ma鈥檔 Zawati, George Thanassoulis, Jamie Engert, Jeff Xia, and Daniela Buhas (涩里番)
笔补谤迟苍别谤(蝉):听, Kyoto University (Japan), (Belgium), (Singapore), and (厂飞颈迟锄别谤濒补苍诲)听
Project duration: 3 years
Relevant D2R Axes: Population Studies and Genomic Medicine (Axes 1),听RNA Therapeutics (Axes 2), Bioprocessing, Biomanufacturing, and Nanotechnology (Axes 3),听Clinical Research, Acceleration, and Implementation (Axes 4),听Data Science, Bioinformatics, and Computing in Personalized Medicine (Axes 5),听Ethical, Socioeconomic, and Cultural Dimensions in Genomic Research (Axes 6)听
A Canada-Germany Partnership for tackling Immune Mediated Disorders (CAGE4IMDs)
This partnership between 涩里番's Victor Phillip Dahdaleh Institute of Genomic Medicine, the German Cancer Research Center (DKFZ), and Charit茅鈥揢niversit盲tsmedizin听Berlin has the objective听to听establish听collaborative opportunities against immune-mediated disorders (IMDs), including Cancers and Rare Diseases. Specifically, it focuses on (1) Developing and adopting cutting-edge single-cell and spatial omics approaches and liquid biopsy methods, (2) Addressing understudied topics, including exposomes (3) Developing computational and mathematical techniques to interpret biology and health data, (4) Leveraging patient cohorts difficult to access in a single institute, and (5) Training the next generation of researchers and highly qualified personnel (HQP).听
Principal Investigators:听Mark Lathrop and听Yasser Riazalhosseini (涩里番)
Co-Investigators: Rosie听Scuccimarri,听Piya听Lahiry, Hamed听Najafabadi, Nada Jabado, Loic Binan, David Langlais, Yann Joly, Jianguo (Jeff) Xia, Ioannis听Ragoussis, Ines听Colmegna, Guillaume Bourque, Livia Garzia, Claudia Kleinman, and Mark Basik (涩里番)
Collaborators: Ian Watson, Corina Nagy, Gerald听Batist, Adriana听Aguilar, Jorg听Fritz, Matthieu听Allez, Shabnam听Radbakhsh, Shreeharsha Tarikere, Mathieu Mancini, and Ciriaco Piccirillo (涩里番)听
Partners:听,听,
Project duration: 3 years
Relevant D2R Axes: RNA Therapeutics (Axes 2), Clinical Research, Acceleration, and Implementation (Axes 4),听Data Science, Bioinformatics, and Computing in Personalized Medicine (Axes 5)听
